Receive Windhover's unique market insight fast with our free alert
service 'Windhover's Update', including the latest abstracts
and summaries from:
• IN VIVO
• Start-Up
• The RPM Report
• Medtech Insight
Sign up
now
|
|
|
Reprints, Electronic Licenses, Distribution Rights and Academic Use
Print and electronic reprints from Windhover Information are available for purchase to complement your marketing efforts. Windhover’s expert, in-depth editorial content provides an objective perspective regarding your products, services and company to investors, shareholders, potential partners and others.
Ideal for use with…
- Trade Shows, Conferences and Seminars
- Customer Communications
- Public Relations
- Media Kits
- Education and Training Programs
- Web Content
- Investor Relations
- E-marketing
Product Offerings
- Print Reprints
Optional customization available. - Online Article Licensing
Permission to post PDF of article for online use.
Rates available for 6-months, 12-months and unlimited use. - E-Prints – Permission to email PDF of article
Rates based on number of emails sent. - Intranet Article Licensing
Unlimited use available for internal client use only. - Academic Rates Available
To obtain a price quote and/or additional product information - please contact:
Pat Cardone
Phone:
(203) 838-4401 x124
Email:
p.cardone@elsevier.com
|
|
 |
|
 |
|
|
| |
 |
Biopharma Trends: Nowhere To Go But Up
Biopharmaceutical trends in 2008 were fundamentally altered by the global financial crisis. And 2009's events were similarly impacted by the ongoing recovery. . . [MORE] (IN VIVO)
The A-List: 2009's Trend-Shaping Series A Financings
New company creation slipped significantly in 2009 as venture capitalists conserved capital and supported existing portfolio companies. . . [MORE] (Start-Up)
Stent Market Doldrums Push Interest Elsewhere
The new realities of the drug-eluting stent market are evident in recent sales results from the big competitors, driving many of them to branch into other higher growth areas. . . [MORE] (Medtech Insight)
The Future of Pharma: The Scale to Fail
The pharmaceutical sector saw a wave of major consolidation in 2009. There are a number of lessons to be learned from the M&A activity that can be applied to the New Year, including the increasing need to get bigger in order to absorb the R&D misses. . . [MORE] (The RPM Report)
Read
more from the latest:
IN VIVO,
Start-Up,
The RPM Report,
Medtech Insight, "The Pink Sheet",
"The Pink Sheet" DAILY,
"The Rose Sheet",
"The Tan Sheet",
PharmAsia News,
Pharmaceutical Approvals Monthly, and
"The Gray Sheet".
|
|
|
|
| |
|
|
|
|
|
